Celltrion launches Omlyclo in Brazil, eyes Latin America growth

Celltrion said Tuesday it has officially launched its autoimmune disease treatment Omlyclo in Brazil, the largest pharmaceutical market in Latin America, as part of its push to expand in the region. Omlyclo, a biosimilar referencing omalizumab, is indicated for conditions including asthma and chronic spontaneous urticaria. The launch positions Celltrion as an early entrant in Brazil’s biosimilar market, where demand for cost-effective biologics is growing.